bluebird bio
60 Binney St
Cambridge
MA
02142
United States
Tel: 339-499-9300
Website: http://www.bluebirdbio.com/
Email: info@bluebirdbio.com
About bluebird bio
bluebird bio is leading the gene therapy revolution. We have nearly 15 years of scientific and clinical experience at the forefront of gene therapy, with deep expertise in rare diseases and immuno-oncology, a proven scientific and lentiviral-based manufacturing platform, and a complementary set of tools such as gene editing.
We are a patient- and purpose-driven, product-oriented organization. Our diverse flock of bluebirds is united by a singular focus: a passionate commitment to changing the lives of patients and supporting each other on this journey. At bluebird bio, we will work like crazy with a never-give-up, little-but-mighty attitude, as exemplified by our namesake, the Eastern Bluebird.
we are always innovating, never stopping and never giving up.
Stock symbol: BLUE
Stock exchange: NASDAQ
Our birds are constantly reminded of the difference they can make on the lives of patients and in the lives of their fellow birds – no matter what their title may be. Whether it’s running a successful experiment in the lab, developing a new and efficient process for your team, being an inspiring mentor for those around you, or always being a friendly face in the morning, we can all make an impact and we can all make a difference. How will you Make Your Mark?
338 articles with bluebird bio
-
bluebird bio to Present at Jefferies Cell Therapy Virtual Summit
9/28/2020
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jefferies Cell Therapy Virtual Summit, Tuesday, October 6, at 2:00 p.m. ET. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com . Replays of the
-
bluebird bio’s LentiGlobin™ for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency
9/23/2020
EMA’s PRIME program designed to optimize development and expedite evaluation of innovative medicines for patients with high unmet need
-
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)
9/22/2020
FDA set a target action date of March 27, 2021 Ide-cel is the first CAR T cell therapy accepted for regulatory review for multiple myeloma PRINCETON, N.J., & CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc . (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review their Biologics License Application (BLA) for idecabtagene vicle
-
Bristol Myers Squibb and bluebird bio are eying a potential quick approval for a CAR-T treatment for multiple myeloma after the U.S. Food and Drug Administration accepted the Biologics License Application under priority review.
-
bluebird bio Announces September Investor Events
9/2/2020
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: 2020 Wells Fargo Virtual Healthcare Conference, Thursday, September 10, at 4:00 pm ET Morgan Stanley 18th Annual Global Healthcare Conference, Tuesday, September 15, at 1:15 pm ET BofA Global Healthcare Conference 2020, Friday, September 18, at 10:05
-
bluebird bio Presents New Results from Clinical Development Program of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD), Including Updated Long-Term Data, at the 46th Annual Meeting of the EBMT
8/29/2020
Long-term results from Phase 2/3 Starbeam study (ALD-102/LTF-304) suggest durability of response post eli-cel with all 20 patients who were free of major functional disabilities (MFDs) at two years (out of 23 evaluable patients) remaining MFD-free through last available follow-up, including all 10 patients who reached at least Year 5 follow-up visit
-
bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting
8/17/2020
bluebird bio, Inc. announced that new data from the clinical development program for its investigational elivaldogene autotemcel gene therapy in patients with cerebral adrenoleukodystrophy, including data from the Phase 2/3 Starbeam study and available data from the Phase 3 ALD-104 study
-
bluebird bio Appoints Denice Torres to Board of Directors
8/11/2020
bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has appointed Denice Torres to its Board of Directors. “We’re excited to welcome Denice to the Board to help guide bluebird as we reach the next stage in our evolution,” said Nick Leschly, chief bluebird. “Denice brings valuable perspective and exceptional industry insights based on over 25 years of executive management experience in pharmaceuticals, medic
-
bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress
8/5/2020
First sickle cell patient treated with drug product manufactured with suspension-based lentiviral vector in HGB-206
-
bluebird bio Announces August Investor Event
7/31/2020
bluebird bio, Inc. (NASDAQ: BLUE) today announced members of the management team will participate in the Canaccord Genuity 40 th Annual Growth Conference, Wednesday, August 12, at 10:30 a.m. ET. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com . A rep
-
Clinical Catch-Up: June 8-12
6/15/2020
It was a fairly busy week with clinical trial updates and announcements. Here’s a look. -
New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1/2 Clinical Study of bluebird bio’s LentiGlobin™ Gene Therapy for Sickle Cell Disease at 25th EHA Congress
6/12/2020
99.5% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with a history of VOCs and ACS (n=14) who had at least six months follow-up
-
Majority of Evaluable Patients Across Genotypes Achieve Transfusion Independence and Maintain It with Near-Normal Hemoglobin Levels in Phase 3 Studies of betibeglogene autotemcel Gene Therapy Presented at EHA Congress
6/12/2020
89% of evaluable patients (17/19) with transfusion-dependent β-thalassemia who do not have a β0/β0 genotype achieved transfusion independence with 11.9 g/dL median weighted average total hemoglobin (Hb) level in HGB-207
-
Biotech companies from across the globe are posting strong data at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress. Below is a roundup of some of the news coming out of the virtual conference.
-
bluebird bio Announces That Its 2020 Annual Meeting of Stockholders Will Be Held in Virtual Format
6/3/2020
bluebird bio, Inc. announced that, due to the public health and safety concerns related to the novel coronavirus pandemic, to support the health and well-being of its directors, employees and stockholders, the location of the Company’s 2020 Annual Meeting of Stockholders has been changed to a virtual format only.
-
Numerous biopharmaceutical companies and researchers are presenting research and clinical trial results, and many have been announcing their plans for several weeks.
-
bluebird bio Announces Live Webcast of EHA Data Review and June Investor Events
5/28/2020
bluebird bio, Inc. (NASDAQ: BLUE) today announced that the company will host a live webcast to review new data presented at the European Hematology Association (EHA) Annual Meeting on Friday, June 12 at 8:00 am ET. Investors may listen to the call on June 12, 2020 at 8:00 am ET by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. Please refer to conferenc
-
bluebird bio Announces Pricing of Public Offering of Common Stock - May 19, 2020
5/19/2020
bluebird bio, Inc. announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $55.00 per share, before underwriting discounts.
-
bluebird bio Announces Proposed Public Offering of Common Stock - May 18, 2020
5/18/2020
bluebird bio, Inc. announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent of the shares of common stock offered in the public offering.
-
Clinical Catch-Up: May 11-15
5/18/2020
Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.